Jacobson Pharma, Hong Kong’s largest generic drug maker, completed an $85 million IPO on the Hong Kong exchange. Eight of Jacobson’s nine production facilities and almost all of its sales are in Hong Kong. According to the company, it has a 30% share of Hong Kong generic drug revenues, more than the next two companies combined. Jacobson makes generic drugs and TCM products, which it sells to public hospitals and private clinics and pharmacies. The company says it will allocate 45% of the proceeds to strategic acquisitions.
